Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
33.26 -0.30 (-0.89%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 33.26 unch (unch) 16:02 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
32.67
Day High
33.96
Open 32.67
Previous Close 33.56 33.56
Volume 500,900 500,900
Avg Vol 927,550 927,550
Stochastic %K 96.78% 96.78%
Weighted Alpha -21.64 -21.64
5-Day Change +7.29 (+28.07%) +7.29 (+28.07%)
52-Week Range 19.44 - 53.27 19.44 - 53.27
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,160,037
  • Shares Outstanding, K 64,944
  • Annual Sales, $ 47,070 K
  • Annual Income, $ -223,860 K
  • EBIT $ -262 M
  • EBITDA $ -268 M
  • 60-Month Beta 2.22
  • Price/Sales 46.30
  • Price/Cash Flow N/A
  • Price/Book 2.60

Options Overview Details

View History
  • Implied Volatility 94.87% ( -6.72%)
  • Historical Volatility 87.24%
  • IV Percentile 92%
  • IV Rank 52.66%
  • IV High 132.42% on 04/17/25
  • IV Low 53.10% on 11/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 237
  • Volume Avg (30-Day) 232
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 2,977
  • Open Int (30-Day) 3,663

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.92
  • Number of Estimates 11
  • High Estimate -0.76
  • Low Estimate -1.07
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.44 +71.09%
on 04/09/25
Period Open: 31.82
33.96 -2.06%
on 04/25/25
+1.44 (+4.53%)
since 03/25/25
3-Month
19.44 +71.09%
on 04/09/25
Period Open: 44.36
45.31 -26.59%
on 01/27/25
-11.10 (-25.02%)
since 01/24/25
52-Week
19.44 +71.09%
on 04/09/25
Period Open: 33.35
53.27 -37.56%
on 09/26/24
-0.09 (-0.27%)
since 04/25/24

Most Recent Stories

More News
Why Kymera Therapeutics Stock Crushed it This Week

According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (NASDAQ: KYMR) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech...

KYMR : 33.26 (-0.89%)
NFLX : 1,101.53 (+0.42%)
Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

KYMR : 33.26 (-0.89%)
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

KYMR : 33.26 (-0.89%)
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

KYMR : 33.26 (-0.89%)
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

KYMR : 33.26 (-0.89%)
Kymera Therapeutics to Participate in Upcoming March Investor Conferences

KYMR : 33.26 (-0.89%)
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

KYMR : 33.26 (-0.89%)
Kymera Therapeutics to Participate in Upcoming February Investor Conferences

KYMR : 33.26 (-0.89%)
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KYMR : 33.26 (-0.89%)
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

KYMR : 33.26 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 35.21
2nd Resistance Point 34.59
1st Resistance Point 33.92
Last Price 33.26
1st Support Level 32.63
2nd Support Level 32.01
3rd Support Level 31.34

See More

52-Week High 53.27
Fibonacci 61.8% 40.35
Fibonacci 50% 36.35
Last Price 33.26
Fibonacci 38.2% 32.36
52-Week Low 19.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective